{"id":"NCT01030783","sponsor":"AVEO Pharmaceuticals, Inc.","briefTitle":"A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","officialTitle":"A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2012-07","completion":"2013-06","firstPosted":"2009-12-11","resultsPosted":"2019-10-28","lastUpdate":"2019-10-28"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"tivozanib (AV-951)","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"tivozanib (AV-951)","type":"EXPERIMENTAL"},{"label":"sorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.","primaryOutcome":{"measure":"Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.","effectByArm":[{"arm":"Tivozanib (AV-951)","deltaMin":11.9,"sd":null},{"arm":"Sorafenib","deltaMin":9.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":86,"countries":["United States","Argentina","Bulgaria","Canada","Chile","Czechia","France","Hungary","India","Italy","Poland","Romania","Russia","Serbia","Ukraine","United Kingdom"]},"refs":{"pmids":["37146227"],"seeAlso":["http://www.aveopharma.com"]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":259},"commonTop":["Hypertension","Palmar-plantar erythrodysaesthesia syndrome","Diarrhoea","Weight decreased","Fatigue"]}}